Antibody halts effect of dabigatran
The monoclonal antibody idarucizumab is able to counteract the effect of the non-vitamin K antagonist oral anticoagulant dabigatran in the majority of patients. That is the conclusion of a recent publication in The New England Journal of Medicine. These results imply that the irreversibility of effect of dabigatran is now no longer an issue. Continue reading